Cost-Effectiveness of Radiofrequency Catheter Ablation Compared With Antiarrhythmic Drug Therapy for Paroxysmal Atrial Fibrillation
暂无分享,去创建一个
David J Cohen | Mark E Josephson | M. Josephson | P. Zimetbaum | D. Cohen | M. Reynolds | Matthew R Reynolds | Peter Zimetbaum | Ethan Ellis | Tatyana Danilov | Ethan R. Ellis | Tatyana Danilov | D. Cohen | D. Cohen
[1] Mandeep Bhargava,et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.
[2] J. Brazier,et al. The Estimation of a Preference-Based Measure of Health From the SF-12 , 2004, Medical care.
[3] Massimo Santini,et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. , 2008, European heart journal.
[4] J Clémenty,et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.
[5] M. Josephson,et al. Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. , 2003, The American journal of cardiology.
[6] P. Zimetbaum,et al. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. , 2006, American heart journal.
[7] C. Morillo,et al. Cost Comparison of Ablation Versus Antiarrhythmic Drugs As First‐Line Therapy for Atrial Fibrillation: An Economic Evaluation of the RAAFT Pilot Study , 2009, Journal of cardiovascular electrophysiology.
[8] S. Lévy,et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. , 2007, Journal of the American College of Cardiology.
[9] F. Morady,et al. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. , 2006, Journal of the American College of Cardiology.
[10] Mark L. Greenberg,et al. Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation , 1999, Annals of Internal Medicine.
[11] D. Singer,et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.
[12] Affirm Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. , 2003, Journal of the American College of Cardiology.
[13] Hakan Oral,et al. Pulmonary Vein Isolation for Paroxysmal and Persistent Atrial Fibrillation , 2002, Circulation.
[14] J. Brazier,et al. The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.
[15] C. Morillo,et al. Cost Comparison of Catheter Ablation and Medical Therapy in Atrial Fibrillation , 2007, Journal of cardiovascular electrophysiology.
[16] S. Mickelsen,et al. Atrial Fibrillation Ablation Leads to Long-Term Improvement of Quality of Life and Reduced Utilization of Healthcare Resources , 2003, Journal of Interventional Cardiac Electrophysiology.
[17] Antonio De Simone,et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). , 2006, European heart journal.
[18] R. Falk,et al. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. , 1998, Archives of internal medicine.
[19] B. O'brien,et al. Cost-Effectiveness of Rhythm versus Rate Control in Atrial Fibrillation , 2004, Annals of Internal Medicine.
[20] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[21] G. Mensah,et al. Increasing Trends in Hospitalization for Atrial Fibrillation in the United States, 1985 Through 1999: Implications for Primary Prevention , 2003, Circulation.
[22] Matthew Reynolds,et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[23] Matthew R. Reynolds,et al. Treatment of Atrial Fibrillation With Antiarrhythmic Drugs or Radiofrequency Ablation: Two Systematic Literature Reviews and Meta-Analyses , 2009, Circulation. Arrhythmia and electrophysiology.
[24] Elia Biganzoli,et al. Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation. Arrhythmia and electrophysiology.
[25] V. Santinelli,et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. , 2006, Journal of the American College of Cardiology.
[26] P. Zimetbaum,et al. Quality of Life in Atrial Fibrillation: Measurement Tools and Impact of Interventions , 2008, Journal of cardiovascular electrophysiology.
[27] F. Sacher,et al. Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: The A4 Study , 2008, Circulation.
[28] S Nattel,et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. , 2000, The New England journal of medicine.
[29] Silvia G. Priori,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC , 2006 .
[30] A L Waldo,et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.
[31] R. Mantovan,et al. Early complications of pulmonary vein catheter ablation for atrial fibrillation: a multicenter prospective registry on procedural safety. , 2007, Heart rhythm.
[32] A Briggs,et al. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.
[33] J. Ware,et al. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.
[34] D. Lin,et al. Reversal of Left Ventricular Dysfunction Following Ablation of Atrial Fibrillation , 2007, Journal of cardiovascular electrophysiology.
[35] Frank Bogun,et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. , 2006, The New England journal of medicine.
[36] David O. Martin,et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. , 2004, Journal of the American College of Cardiology.
[37] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[38] J. Ruskin,et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.
[39] John V. Wylie,et al. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. , 2008, Archives of internal medicine.
[40] Ottavio Alfieri,et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. , 2003, Journal of the American College of Cardiology.
[41] Ware J.E.Jr.,et al. THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .
[42] H. Halperin,et al. Long-term single procedure efficacy of catheter ablation of atrial fibrillation , 2006, Journal of Interventional Cardiac Electrophysiology.
[43] S. Hohnloser,et al. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial , 2000, The Lancet.
[44] D. Shah,et al. Cost Analysis of Catheter Ablation for Paroxysmal Atrial Fibrillation , 2003, Pacing and clinical electrophysiology : PACE.
[45] D. Reda,et al. Amiodarone versus sotalol for atrial fibrillation. , 2005, The New England journal of medicine.
[46] E. Arias,et al. United States life tables, 2005. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[47] Christopher X. Wong,et al. INCREASING TRENDS IN HOSPITALIZATION FOR ATRIAL FIBRILLATION IN AUSTRALIA: 1998-2008 , 2010 .
[48] Amiodarone to Prevent Recurrence of Atrial Fibrillation , 2000 .
[49] Michael A. E. Schneider,et al. Circumferential pulmonary vein isolation with the cryoballoon technique results from a prospective 3-center study. , 2008, Journal of the American College of Cardiology.
[50] P. Zimetbaum,et al. Healthcare Resource Utilization and Costs Associated with Recurrent Episodes of Atrial Fibrillation: The FRACTAL Registry , 2007, Journal of cardiovascular electrophysiology.
[51] J Clémenty,et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. , 1997, Circulation.
[52] Prashanthan Sanders,et al. Catheter ablation for atrial fibrillation in congestive heart failure. , 2004, The New England journal of medicine.